سامانه مدیریت نشریات علمی دانشگاه علوم پزشکی مشهد

Motamed Shariati, Mehrdad. (1403). Precision Medicine in Age-Related Macular Degeneration: Current Approaches and Future Directions. , 12(1), 27-31. doi: 10.22038/rcm.2025.81807.1503
Mehrdad Motamed Shariati. "Precision Medicine in Age-Related Macular Degeneration: Current Approaches and Future Directions". , 12, 1, 1403, 27-31. doi: 10.22038/rcm.2025.81807.1503
Motamed Shariati, Mehrdad. (1403). 'Precision Medicine in Age-Related Macular Degeneration: Current Approaches and Future Directions', , 12(1), pp. 27-31. doi: 10.22038/rcm.2025.81807.1503
Motamed Shariati, Mehrdad. Precision Medicine in Age-Related Macular Degeneration: Current Approaches and Future Directions. , 1403; 12(1): 27-31. doi: 10.22038/rcm.2025.81807.1503

Precision Medicine in Age-Related Macular Degeneration: Current Approaches and Future Directions

Reviews in Clinical Medicine
مقاله 4، دوره 12، شماره 1، خرداد 2025، صفحه 27-31    اصل مقاله (768.88 K)
نوع مقاله: Review
شناسه دیجیتال (DOI): 10.22038/rcm.2025.81807.1503
نویسنده
Mehrdad Motamed Shariati*
Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
چکیده
Age-related macular degeneration (AMD) is the leading cause of vision loss in the elderly, significantly impacting their quality of life. AMD is classified into two main types: dry (non-neovascular) and wet (neovascular) AMD. While the dry form is more prevalent, the wet form is associated with more severe vision impairment. The variability of AMD, influenced by genetic, environmental, and lifestyle factors, presents a significant challenge in its management. Precision medicine, which tailors healthcare according to individual differences, has emerged as a promising approach for diagnosing, treating, and preventing AMD. This represents a paradigm shift in the management of AMD. By customizing treatments based on individual genetic, environmental, and lifestyle factors, precision medicine can potentially improve outcomes for AMD patients. This review comprehensively evaluates current precision medicine strategies in AMD, addresses existing challenges, and explores the potential for personalized interventions to enhance patient outcomes.
کلیدواژه‌ها
Stratified medicine؛ Age-related macular degeneration؛ Genetic biomarkers؛ Personalized therapeutics؛ Proteomics
مراجع
  1. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. The Lancet. 2012;379(9827):1728-38. doi:10.1016/S0140-6736(12)60282-7 [PMid:22559899]
  2. Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. The Lancet. 2018;392(10153):1147-59. doi:10.1016/S0140-6736(18)31550-2 [PMid:30303083]
  3. de Jong EK, Geerlings MJ, den Hollander AI. Age-related macular degeneration. Genetics and genomics of eye disease. 2020:155-80. doi: 10.1016/B978-0-12-816222-4.00010-1
    [PMCid:PMC7368101]
  4. Cascella R, Strafella C, Caputo V, Errichiello V, Zampatti S, Milano F, et al. Towards the application of precision medicine in Age-Related Macular Degeneration. Progress in Retinal and Eye Research. 2018;63:132-46. doi:10.1016/j.preteyeres.2017.11.004 [PMid:29197628]
  5. Lorés-Motta L, de Jong EK, den Hollander AI. Exploring the use of molecular biomarkers for precision medicine in age-related macular degeneration. Molecular diagnosis & therapy. 2018;22(3):315-43. doi:10.1007/s40291-018-0332-1 [PMid:29700787]
  6. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacological reports. 2006;58(3):353.
  7. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Archives of ophthalmology. 2004;122(4):598-614. doi: 10.1001/archopht.122.4.598 [PMid:15078679]
  8. Deng Y, Qiao L, Du M, Qu C, Wan L, Li J, et al. Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes & diseases. 2022;9(1):62-79. doi:10.1016/j.gendis.2021.02.009 [PMid:35005108]
  9. Shughoury A, Sevgi DD, Ciulla TA. Molecular genetic mechanisms in age-related macular degeneration. Genes. 2022;13(7):1233. doi:10.3390/genes13071233 [PMid:35886016]
  10. Han X, Ong J-S, Hewitt AW, Gharahkhani P, MacGregor S. The effects of eight serum lipid biomarkers on age-related macular degeneration risk: a Mendelian randomization study. International Journal of Epidemiology. 2021;50(1):325-36. doi:10.1093/ije/dyaa178 [PMid:33211829]
  11. Weaver C, Cyr B, de Rivero Vaccari JC, de Rivero Vaccari JP. Inflammasome proteins as inflammatory biomarkers of age-related macular degeneration. Translational vision science & technology. 2020;9(13):27. doi:10.1167/tvst.9.13.27 [PMid:33364081]
  12. Metrangolo C, Donati S, Mazzola M, Fontanel L, Messina W, D'alterio G, et al. OCT Biomarkers in Neovascular Age‐Related Macular Degeneration: A Narrative Review. Journal of ophthalmology. 2021;2021(1):9994098. doi:10.1155/2021/9994098 [PMid:34336265]
  13. Kalra G, Kar SS, Sevgi DD, Madabhushi A, Srivastava SK, Ehlers JP. Quantitative imaging biomarkers in age-related macular degeneration and diabetic eye disease: a step closer to precision medicine. Journal of Personalized Medicine. 2021;11(11):1161.
    doi: 10.3390/jpm11111161 [PMid:34834513]
  14. den Hollander AI, Mullins RF, Orozco LD, Voigt AP, Chen H-H, Strunz T, et al. Systems genomics in age-related macular degeneration. Experimental eye research. 2022;225:109248.
    doi:10.1016/j.exer.2022.109248 [PMid:36108770]
  15. Oca AI, Pérez-Sala Á, Pariente A, Ochoa R, Velilla S, Peláez R, et al. Predictive biomarkers of age-related macular degeneration response to anti-VEGF treatment. Journal of Personalized Medicine. 2021;11(12):1329. doi:10.3390/jpm11121329 [PMid:34945801]
  16. Tan T-E, Wong TY, Ting DSW. Artificial intelligence for prediction of anti-VEGF treatment burden in retinal diseases: towards precision medicine. Ophthalmology Retina. 2021;5(7):601-3.
    doi:10.1016/j.oret.2021.05.001 [PMid:34243967]
  17. Scholl HP. Complement Inhibition in Age-Related Macular Degeneration-Treat Early! JAMA ophthalmology. 2022;140(3):250-1. doi: 10.1001/jamaophthalmol.2021.6068 [PMid:35113132]
  18. Qin S, Dong N, Yang M, Wang J, Feng X, Wang Y. Complement Inhibitors in Age‐Related Macular Degeneration: A Potential Therapeutic Option. Journal of immunology research. 2021;2021(1):9945725. doi: 10.1155/2021/9945725 [PMid:34368372]
  19. Gkouskou KK, Grammatikopoulou MG, Vlastos I, Sanoudou D, Eliopoulos AG. Genotype-guided dietary supplementation in precision nutrition. Nutrition Reviews. 2021;79(11):1225-35.
    doi:10.1093/nutrit/nuaa132 [PMid:33367884]
  20. Khanani AM, Thomas MJ, Aziz AA, Weng CY, Danzig CJ, Yiu G, et al. Review of gene therapies for age-related macular degeneration. Eye. 2022;36(2):303-11.
    doi:10.1038/s41433-021-01842-1 [PMid:35017696]
  21. de Guimaraes TAC, Georgiou M, Bainbridge JW, Michaelides M. Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions. British Journal of Ophthalmology. 2021;105(2):151-7. doi:10.1136/bjophthalmol-2020-316195 [PMid:32269060]
  22. Sarkar A, Junnuthula V, Dyawanapelly S. Ocular therapeutics and molecular delivery strategies for neovascular age-related macular degeneration (Namd). International Journal of Molecular Sciences. 2021;22(19):10594. doi:10.3390/ijms221910594 [PMid:34638935]
  23. Mammadzada P, Corredoira PM, André H. The role of hypoxia-inducible factors in neovascular age-related macular degeneration: a gene therapy perspective. Cellular and Molecular Life Sciences. 2020;77:819-33. doi:10.1007/s00018-019-03422-9 [PMid:31893312]
  24. Lombardo M, Serrao S, Lombardo G. Challenges in age-related macular degeneration: From risk factors to novel diagnostics and prevention strategies. Frontiers in Medicine. 2022;9:887104.
    doi:10.3389/fmed.2022.887104 [PMid:35733877]
  25. Hartl D, de Luca V, Kostikova A, Laramie J, Kennedy S, Ferrero E, et al. Translational precision medicine: an industry perspective. Journal of translational medicine. 2021;19(1):245.
    doi:10.1186/s12967-021-02910-6 [PMid:34090480]
  26. Faulkner E, Holtorf A-P, Liu CY, Lin H, Biltaj E, Brixner D, et al. Being precise about precision medicine: what should value frameworks incorporate to address precision medicine? A report of the personalized precision medicine special interest group. Value in Health. 2020;23(5):529-39.
    doi:10.1016/j.jval.2019.11.010 [PMid:32389217]
  27. Zhang S, Yang Y, Chen J, Su S, Cai Y, Yang X, et al. Integrating Multi-omics to Identify Age-Related Macular Degeneration Subtypes and Biomarkers. Journal of Molecular Neuroscience. 2024;74(3):1-16. doi:10.1016/j.neuroscience.2023.11.021 [PMid:37913862]
  28. Romond K, Alam M, Kravets S, Sisternes Ld, Leng T, Lim JI, et al. Imaging and artificial intelligence for progression of age-related macular degeneration. Experimental Biology and Medicine. 2021;246(20):2159-69.doi: 10.1177/15353702211031547 [PMid:34404252]
  29. Crincoli E, Sacconi R, Querques L, Querques G. Artificial intelligence in age-related macular degeneration: state of the art and recent updates. BMC ophthalmology. 2024;24(1):121.
    doi:10.1186/s12886-024-03381-1 [PMid:38491380]
  30. Galindo-Camacho RM, Blanco-Llamero C, da Ana R, Fuertes MA, Señoráns FJ, Silva AM, et al. Therapeutic approaches for age-related macular degeneration. International journal of molecular sciences. 2022;23(19):11769. doi:10.3390/ijms231911769 [PMid:36233066]
  31. Di Carlo E, Augustin AJ. Prevention of the onset of age-related macular degeneration. Journal of clinical medicine. 2021;10(15):3297. doi:10.3390/jcm10153297 [PMid:34362080]
  32. Wang J, Li M, Geng Z, Khattak S, Ji X, Wu D, et al. Role of oxidative stress in retinal disease and the early intervention strategies: a review. Oxidative Medicine and Cellular Longevity. 2022;2022(1):7836828. doi: 10.1155/2022/7836828 [PMid:36275903]
  33. Maeda T, Sugita S, Kurimoto Y, Takahashi M. Trends of stem cell therapies in age-related macular degeneration. Journal of Clinical Medicine. 2021;10(8):1785. doi:10.3390/jcm10081785 [PMid:33923985]

 

آمار
تعداد مشاهده مقاله: 92
تعداد دریافت فایل اصل مقاله: 35